Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775873 | 0.84 | TAAR1 (0.44) | TAAR1LMNATSHRADRA1D | |
| SCHEMBL14366318 | 0.75 | TSHR (0.46) | TAAR1LMNATSHRADRA1DADRA2A | |
| SCHEMBL2187612 | 0.74 | CYP17A1 (0.60) | TAAR1TSHRHTR1AADRA2AADRA2B | |
| SCHEMBL1679282 | 0.73 | TAAR1 (0.64) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL5757254 | 0.72 | MGMT (0.39) | TAAR1LMNATSHRADRA1DADRA2A | |
| SCHEMBL17321287 | 0.71 | ADRA1D (0.51) | TAAR1LMNATSHRADRA1DKDM4E | |
| SCHEMBL8112129 | 0.71 | ADRA1D (0.37) | TAAR1LMNATSHRADRA1DADRA2A | |
| SCHEMBL28103549 | 0.71 | ADRA2A (0.69) | TAAR1LMNATSHRHTR1AADRA2A | |
| SCHEMBL559559 | 0.71 | TAAR1 (0.56) | TAAR1LMNATSHRADRA1DADRA2A | |
| SCHEMBL5548998 | 0.70 | TAAR1 (0.47) | TAAR1HTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | claimed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| CN-101918358-B | Novel vitamin D receptor activators and methods of manufacture | ABBVIE (US) | 2015-10-14 | — | — | CN | disclosed |
| CN-104211626-A | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBVIE INC | 2014-12-17 | — | — | CN | disclosed |
| CN-102816165-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB | 2012-12-12 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101925599-A | Azabicyclic alkane derivatives as the biaryl substituted of nicotinic acetylcholine receptor activity modulators | ABBOTT LAB | 2010-12-22 | — | — | CN | disclosed |
| CN-101918358-A | Novel vitamin D receptor activators and methods of manufacture | ABBOTT LAB | 2010-12-15 | — | — | CN | disclosed |
| CN-101918409-A | The diazabicycloalkane derivatives of biaryl substituted | ABBOTT LAB | 2010-12-15 | — | — | CN | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885LMNA 2048/4885TSHR 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.